Nocturnal Actigraph Scratch Assessment (NASA)04/16/2024 - 04/16/2025 (PI)
Takeda Development Center Americas, Inc.
PD Annotation: Manual Video Labeling of Motor Manifestations of Parkinson's Disease Using the ELAN Video Annotation Software08/22/2017 - 10/31/2024 (PI)
Pfizer, Inc.
Practical Creative Solutions Training Support06/03/2015 - 06/02/2024 (PI)
Practical Creative Solutions
QUANTIFICATION OF IMPROVEMENT IN SCRATCH BEHAVIOR AND SLEEP IN CHILDREN WITH ATOPIC DERMATITIS ON CRISABOROLE OINTMENT, 2% PF-0693016412/21/2021 - 02/29/2024 (PI)
Pfizer, Inc.
INTEGRATION OF MOBILE SENSING DEVICES AND THE BALANCE MASTER PLATFORM FOR PREDICTION OF FALLS11/06/2019 - 12/06/2023 (PI)
Biogen, Inc.
Geriatric Anorexia Study 2.0 (GAS2) Novel Digital Endpoints in Geriatric Anorexia11/18/2021 - 11/18/2023 (PI)
Pfizer, Inc.
Clinical Research Collaboration Agreement between Boston University and Biogen Inc.07/30/2018 - 07/29/2023 (PI)
Biogen, Inc.
Geriatric Anorexia Study (GAS) - Novel Digital Endpoints in Geriatric Anorexia11/20/2020 - 11/20/2022 (PI)
Pfizer, Inc.
Wearable Polysomnography In-Lab for One Night in Healthy Subjects12/02/2019 - 12/31/2021 (PI)
Biogen, Inc.
Quantification of Improvement in Scratch Behavior and Sleep in Patients with Atopic Dermatitis on Standard of Care Treatment12/12/2018 - 12/31/2021 (PI)
Pfizer, Inc.
Showing 10 of 18 results.
Show All Results
Clinical Research Collaboration Agreement between Boston University and Pfizer Inc. -- Atopic Dermatitis Study08/08/2018 - 12/31/2020 (PI)
Pfizer, Inc.
PFE Metholology Study12/22/2017 - 12/31/2019 (PI)
Pfizer, Inc.
Be Safe Support Agreement07/15/2017 - 12/31/2019 (PI)
BeSafe Technologies, Inc.
23andMe Portal Validation Study12/19/2017 - 12/31/2018 (PI)
Pfizer, Inc.
Human Neurobiology Laboratory Support Contract with Pfizer01/01/2014 - 12/31/2018 (PI)
Pfizer, Inc.
Boston University Healthcare Emergency Management Program Work Order #102/10/2017 - 03/31/2017 (PI)
Everbridge, Inc.
Boston University Healthcare Emergency Management Program11/21/2016 - 12/23/2016 (PI)
Everbridge, Inc.
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Doses of PF-0664975103/16/2015 - 12/16/2015 (PI)
Pfizer, Inc.